A Study to Establish a Registry of Deep Brain Stimulation with the VERCISE™ System

Overview

About this study

The purpose of this study is to document characteristics of real-world outcomes for Boston Scientific Corporation’s commercially approved Vercise™ System for Deep Brain Stimulation (DBS) when used according to the applicable Directions for Use.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Understands the study requirements and the treatment procedures.
  • Willing and able to provide written informed consent before any study-specific tests or procedures are performed.
  • Plans to receive currently available Vercise™ System and/or any new Commercially Approved components (i.e., leads, extension, Adaptor, CP, etc.) compatible with the Vercise System.
  • Meets criteria established in the locally applicable Vercise™ System.
  • Directions for Use (DFU) for Parkinson’s disease.
  • At least 18 years old.

Exclusion Criteria:

  • Meets any contraindication in the Vercise™ System locally applicable Directions for Use.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Jacksonville, Fla.

Mayo Clinic principal investigator

Ryan Uitti, M.D.

Open for enrollment

Contact information:

Anne Martin B.S.

(904) 953-2255

Martin.Anne@mayo.edu

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available

.
CLS-20470671

Mayo Clinic Footer